FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of medicine, in particular to urology, and may be used to treat prostate-related diseases of an individual. Initial booster dose of one or more active materials and/or prodrugs are administered to an individual in a non-obligatory manner, and pharmaceutical composition with controlled release including one or more active materials in biodegradable ceramic carrier is locally introduced into prostate gland. Biodegradable hydrating ceramic material may be selected from the group consisting of non-hydrated or hydrated calcium sulfate, calcium phosphate, calcium carbonate, calcium fluoride, calcium silicate, magnesium sulfate, magnesium phosphate, magnesium carbonate, magnesium fluoride, magnesium silicate, barium sulfate, barium phosphate, barium carbonate, barium fluoride, barium silicate or their mixtures. In a particular version of realisation, biodegradable hydrating ceramic material is non-hydrated or hydrated calcium sulfate. Also a set is used, representing initial booster dose of one or more active materials and/or prodrugs and the second component representing pharmaceutical composition with controlled release including one or more active materials in biodegradable ceramic carrier, and their application.
EFFECT: method provides for maximum therapeutic effect, with considerable reduction of toxicity.
54 cl, 7 tbl, 10 ex, 5 dwg
Title | Year | Author | Number |
---|---|---|---|
BIOLOGICALLY RESOLVING COMPOSITION WITH CONTROLLED RELEASE | 2007 |
|
RU2405537C2 |
METHOD OF TREATMENT OF ANDROGEN ALOPECIA WITH 5-ALPHA-REDUCTASE INHIBITORS | 1994 |
|
RU2173152C2 |
COMBINATION OF THERAPEUTICAL AGENTS (FOR EXAMPLE, CHLOROPROMAZINE AND PENTAMIDINE) FOR TREATING NEOPLASTIC DISORDERS | 2001 |
|
RU2286769C2 |
OCTREOTIDE IMPLANT CONTAINING RELEASING SUBSTANCE | 2009 |
|
RU2521291C2 |
DOSAGE FORM AND USE OF DIETHYLSTILBESTROL FOR TREATING PROSTATE CANCER OR BREAST CANCER | 2012 |
|
RU2602296C2 |
GnRH ANALOGUE-CONTAINING COMPOSITIONS WITH DELAYED RELEASE | 2010 |
|
RU2549490C2 |
COMBINED THERAPY FOR SKIN DISORDERS | 2011 |
|
RU2603479C2 |
ABIRATERONE PRODRUGS | 2020 |
|
RU2822219C2 |
METHOD FOR INDUCING SELECTIVE DRUG ABLATION OF THE PROSTATE GLAND WITHOUT NERVE DAMAGE, WHILE PRESERVING THE SEXUAL FUNCTION | 2019 |
|
RU2776047C1 |
METHODS FOR ADMINISTRATION OF 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOLE-2-YL)PIPERIDINE-2,6-DIONE IN CERTAIN TYPES OF LEUKEMIA | 2006 |
|
RU2406501C2 |
Authors
Dates
2010-11-27—Published
2006-03-31—Filed